Uscom Limited AI Stock Analysis
Want to see AU:UCM full AI Analyst Report?
Uscom Limited (UCM) AI Stock Analysis
Uscom Limited
(ASX:UCM)
Uscom Limited's overall stock score of 43 reflects significant challenges, primarily driven by poor financial performance with declining revenues, persistent losses, negative equity, and high leverage. Technical indicators also suggest a bearish trend despite oversold conditions, while valuation remains neutral due to negative earnings and lack of dividends. Financial health is the most critical concern for investors.
Uscom Limited (UCM) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.12M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- -0.71
- Revenue Growth
- -52.22%
- EPS Growth
- 44.79%
- Country
- Australia
- Employees
- 35
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Uscom Limited Business Overview & Revenue Model
Company Description
Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-inva...
How the Company Makes Money
Uscom generates revenue through the sale of its medical devices, primarily the Uscom 1A, to hospitals, clinics, and healthcare providers. The company also benefits from recurring revenue generated through service contracts, maintenance agreements, an...
Uscom Limited Financial Statement Overview
Summary
Uscom Limited's financial performance is weak, with a sharp revenue decline of 28.98%, persistent net losses (net profit margin of -128.07%), negative equity, high leverage (debt-to-equity ratio of -59.22), and negative cash flows despite a 79.47% improvement in free cash flow growth. While gross margin remains strong at 86.48%, the overall financial health signals significant risks.
Income Statement
15Very NegativeBalance Sheet
10Very NegativeCash Flow
25Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22M | 2.58M | 3.73M | 2.66M | 2.51M | 3.86M |
| Gross Profit | 104.60K | 2.23M | 3.12M | -1.03M | -1.21M | 781.70K |
| EBITDA | -2.69M | -2.81M | -1.51M | -2.50M | -1.84M | -833.84K |
| Net Income | -1.29M | -3.30M | -2.07M | -2.59M | -1.97M | -924.24K |
Balance Sheet | ||||||
| Total Assets | 460.89K | 3.25M | 5.13M | 5.18M | 7.99M | 5.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1,872 | 966.66K | 2.52M | 2.18M | 4.70M | 1.71M |
| Total Debt | 21.09K | 2.26M | 989.28K | 1.09M | 1.31M | 1.43M |
| Total Liabilities | 278.09K | 3.29M | 2.07M | 2.14M | 2.06M | 2.26M |
| Stockholders Equity | 182.80K | -38.22K | 3.06M | 3.04M | 5.94M | 3.08M |
Cash Flow | ||||||
| Free Cash Flow | -2.82M | -2.72M | -1.22M | -1.58M | -1.08M | 21.63K |
| Operating Cash Flow | -2.81M | -2.71M | -1.16M | -1.42M | -967.51K | 54.98K |
| Investing Cash Flow | -44.62K | -68.78K | -57.55K | -151.94K | -115.31K | -33.35K |
| Financing Cash Flow | 691.22K | 1.21M | 1.57M | -952.96K | 4.05M | -281.87K |
Uscom Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.
Uscom Limited Peers Comparison
Overall Rating
AU:CYC47Neutral
AU:4DX46Neutral
AU:UCM43Neutral
AU:IMR41Neutral
AU:EBR39Underperform
AU:IPD39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | AUD 60.04M | -2.98 | -62.14% | ― | 12.05% | -31.71% | |
| 46Neutral | AUD 1.32B | -5.55 | -288.42% | ― | 20.64% | -457.40% | |
| 43Neutral | AUD 3.12M | -1.56 | -1788.57% | ― | -52.22% | 44.79% | |
| 41Neutral | AUD 482.39M | -7.91 | -184.93% | ― | -68.64% | 36.40% | |
| 39Underperform | AUD 131.05M | -1.15 | -143.78% | ― | 1051.49% | 30.45% | |
| 39Underperform | AUD 14.66M | -0.34 | -259.31% | ― | 14.85% | -1.74% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:UCM | Uscom Limited | 0.01 | 0.00 | 0.00% | |
| AU:IPD | Impedimed Limited | 0.01 | -0.02 | -62.16% | |
| AU:CYC | Cyclopharm Limited | 0.48 | -0.19 | -28.27% | |
| AU:4DX | 4DMedical Ltd | 2.19 | 0.71 | 47.97% | |
| AU:EBR | EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh | 0.15 | -0.85 | -84.52% | |
| AU:IMR | Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh | 1.34 | -0.02 | -1.10% |
Uscom Limited Corporate Events
Uscom Limited Announces FY2025 Results and Strategic Plans for FY2026
Uscom Limited, a leader in medical technology, has announced its FY2025 results and outlined drivers for FY2026. The company has achieved significant milestones, including global clinical adoption and sales in 52 countries, supported by over 1,200 pe...
Uscom Limited Approves Disposal of Main Undertaking
Uscom Limited has announced the results of a recent meeting where a resolution was passed to approve the disposal of the company’s main undertaking. The resolution was decided by a poll, with 59.86% voting in favor and 40.14% voting against, indicati...
Uscom Limited Announces Asset Sale Amid Financial Challenges
Uscom Limited is facing a challenging financial situation, exacerbated by global events such as COVID-19, geopolitical tensions, and trade wars, which have significantly impacted its revenue and led to consecutive years of losses. The company has dec...
Uscom Limited Faces Q1 Challenges Amid Global Economic Uncertainty
Uscom Limited reported a challenging first quarter with a decrease in customer receipts and cash on hand, attributed to global economic uncertainties such as US tariff wars and shifts in European public spending. Despite these challenges, the company...
Uscom Limited Announces Digital-First Annual General Meeting
Uscom Limited has announced its Annual General Meeting of Shareholders, scheduled for November 27, 2025, in Sydney. The company will not send physical copies of the meeting notice, opting instead for electronic distribution. Shareholders are encourag...
Uscom Limited Announces 2025 AGM and Key Resolutions
Uscom Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. Key agenda items include the consideration of the company’s financial report for the year ending June 30, 2025, the adoption of the remunera...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 19, 2025
